[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intrabony-defect\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intrabony-defect":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100619052","flapless-periodontal-regeneration-using-hyaluronic-acid-versus-enamel-matrix-derivative-100619052",false,"NCT07339605","Flapless Periodontal Regeneration Using Hyaluronic Acid Versus Enamel Matrix Derivative","Clinical and Radiographic Outcomes After Flapless Approach of Intrabony Defects With the Application of Enamel Matrix Derivative Versus Hyaluronic Acid: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Periodontitis stage III or IV, grade A or B (Tonetti et al., 2017): attachment loss ≥ 5mm, radiographic bone loss extending to to the middle third and beyond, tooth loss ≥4 due to periodontitis, probing depth (PD) ≥ 6mm.\n* Older adults ≥ 18 years. The number per sex shall be balanced.\n* Plaque index (PI) \\\u003C 1 following initial periodontal therapy and hygiene instructions.\n* Bleeding on probing (BoP) ≤ 10%.\n* Only patients with optimal compliance, assessed during etiological therapy, will be selected.\n* At least a 2-3 wall interproximal bone defect with a radiographically moderate or deep intrabony defect (≥3mm), PD≥ 6mm using a Williams probe on uniradicular teeth or mandibular molars without furcation involvement after non-surgical periodontal treatment.\n* Vital teeth or teeth with well-performed root canal treatment.\n* Absence of caries, prosthetic restoration or periapical infection in the tooth to be regenerated.\n* Absence of systemic pathology.\n* Negative history of pregnancy.\n* Signed informed consent.\n* The participant is willing and able to comply with the necessary visits for the treatments and evaluations scheduled during the clinical study.\n\nExclusion Criteria:\n\n* The participant is pregnant, breastfeeding or plans to become pregnant in the next 6 months.\n* Smoking ≥10 cigarettes\u002Fday.\n* Daily alcohol intake \\> 4U.\n* Chronic illness or reduced mental capacity that may influence compliance with the protocol.\n* Medications or drugs that alter the patient's healing or with concomitant oral manifestations that, in the opinion of the investigator, could interfere with the assessment of safety or efficacy.\n* Systemic diseases that may influence treatment such as diabetes mellitus or rheumatoid disease.\n* Allergies to drug compounds.\n* Antibiotic intake 3 months prior to the start of the study or systemic condition requiring antibiotic coverage at the time of periodontal treatment.\n* Periodontal treatment 6 months prior to the start of the study.","ALL","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to radiographically assess the effectiveness of minimally invasive non-surgical technique (MINST) combined with local administration of sodium hypochlorite gel (Perisolv®) and 1.6% cross-linked hyaluronic acid (HA, Hyadent BG®) compared to a neutral formulation of EDTA (Prefgel®) and enamel matrix derivative (EMD, Emdogain® FL) in periodontal regeneration. The main questions it aims to answer are:\n\n* ¿Does the combination of MINST with the local administration of sodium hypochlorite gel and 1.6% cross-linked hyaluronic acid show a potential for periodontal regeneration similar to evaluating clinical and radiographic variables compared to a neutral formulation of EDTA and enamel matrix derivative?\n* ¿What is the patient perception and satisfaction with the received treatment?\n\nResearchers will compare A (MINST with Perisolv® + Hyadent BG®), B (MINST with PrefGel® + Emdogain® FL) and C(MINST without any bioactive product).\n\nThe sample will be distributed according to the following treatments:\n\n* Experimental group: Scaling and root planing (SRP), MINST with Perisolv® + Hyadent BG®.\n* Active comparator group: SRP, MINST with PrefGel® + Emdogain® FL.\n* Control group: SRP, MINST without any bioactive product.\n\nPatients will be screened by a first visit in which they will be assigned their periodontal status. If they meet the eligibility criteria, they will be treated according to the EFP clinical guideline for periodontitis treatment: step I and step II.If the periodontal defect persists at the 12-week re-evaluation, patients will be randomised to treatment A, B or C.\n\nAfter the intervention, all participants will be checked weekly for the first 6 weeks to remove accumulated plaque, and every 3 months for 1 year. Periodontal parameters will be re-evaluated 6 and 12 months after periodontal regenerative intervention.",[26,27,28,29,30,31,32],"Guided Tissue Regeneration, Periodontal \u002F Methods","Dental Enamel Proteins* \u002F Therapeutic Use","Alveolar Bone Loss* \u002F Therapy","Hyaluronic Acid* \u002F Therapeutic Use","Humans","Intrabony Defect","Flapless",[34,35,36,37,38],"Periodontitis","Intrabony defect","Hyaluronic acid","Enamel matrix derivative","Periodontal regeneration","RECRUITING","2026-01-04",{"date":42,"type":43},"2026-01-14","ACTUAL",{"date":45,"type":43},"2024-10-26",{"date":47,"type":20},"2027-07",{"name":49,"class":50},"University of Valencia","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":21,"phases":63,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":4},"100588070","rgd-with-minimally-invasive-non-surgical-technique-in-treatment-of-periodontal-intrabony-defect-100588070","NCT06936605","RGD With Minimally Invasive Non-Surgical Technique in Treatment of Periodontal Intrabony Defect","The Use of Integrin Binding Domain Loaded Hydrogel (RGD) With Minimally Invasive Non-Surgical Technique in Treatment of Periodontal Intrabony Defect (Randomized Clinical Trial Study)","MINST + RGD","Inclusion Criteria:\n\n* • All patients included will have moderate to advanced periodontitis.\n\n  * Patients included in this study will be free from any systemic diseases according to criteria of Modified Cornell Medical Index(10).\n  * Patients who had not undergone any type of regenerative periodontal therapy six months prior to the initial examination.\n\nExclusion Criteria:\n\n* • Patients with systemic diseases, smokers, pregnant (female).\n\n  * Patients received antibiotics or non-steroidal anti-inflammatory drugs six months before the beginning of the study.","55 Years",{"count":62,"type":20},45,[23],"Periodontal regeneration is a complex process that involves coordinated activities and interactions of many cell types, extracellular matrix, cytokines, and specific growth factors to restore tissue integrity. The most important challenge facing periodontal regeneration is cellular insufficiency. Periodontal defects usually have a limited regenerative capacity due to their bounded surface area which is supposed to provide the wound area with a limited number of viable cells and a limited amount of biologic mediators. Cell recruitment and adhesion into the defect area are essential for cells to survive and secrete collagen.\n\nApoptosis is initiated when failure in adhesion in many different cell types occurs. Some periodontal treatment options failed in the reconstruction of the defect due to failure in wound stabilization and subsequent cell adhesion. Many treatment options have been developed to enhance defect stability and cellular recruitment including the use of GTM and different biologics. However, the treatment outcomes vary considerably depending on the level of the defect cellularity and the degree of cell recruitment into the defect area. For maximum outcomes, enhanced stability, vascularity, and biologics-sustained delivery were suggested. The minimally invasive surgical technique (MIST) suggested by Cortellini et al. offers a suitable level of tissue preservation that could help in defect stability and cellular adhesion. It was suggested to promote flap stability, maintain space, and maintain a greater amount of blood supply at the alveolar crest and papillary levels.",[31,66,67],"Periodontal Diseases","Alveolar Bone Loss",[69,70,71],"MINST","RGD","intrabony defect","NOT_YET_RECRUITING","2025-04-17",{"date":75,"type":43},"2025-04-20",{"date":77,"type":20},"2025-04-15",{"date":79,"type":20},"2025-10-20",{"name":81,"class":50},"Minia University"]